Nikulainen, I.; Salminen, A.P.; Högerman, M.; Seikkula, H.; Boström, P.J.; The Finnish National Cystectomy Database Research Group.
Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes. Cancers 2025, 17, 505.
https://doi.org/10.3390/cancers17030505
AMA Style
Nikulainen I, Salminen AP, Högerman M, Seikkula H, Boström PJ, The Finnish National Cystectomy Database Research Group.
Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes. Cancers. 2025; 17(3):505.
https://doi.org/10.3390/cancers17030505
Chicago/Turabian Style
Nikulainen, Ilkka, Antti P. Salminen, Mikael Högerman, Heikki Seikkula, Peter J. Boström, and The Finnish National Cystectomy Database Research Group.
2025. "Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes" Cancers 17, no. 3: 505.
https://doi.org/10.3390/cancers17030505
APA Style
Nikulainen, I., Salminen, A. P., Högerman, M., Seikkula, H., Boström, P. J., & The Finnish National Cystectomy Database Research Group.
(2025). Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes. Cancers, 17(3), 505.
https://doi.org/10.3390/cancers17030505